Search research articles
Contact Us
Filters
Showing results (41-50 of 54) with videos related to
Page
of 6
Sort By:
Journal of Medicinal Chemistry
|
February 17, 2016
Potent and Selective Inhibitors of MTH1 Probe Its Role in Cancer Cell Survival
Jason G Kettle, Husam Alwan, Michal Bista, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
October 31, 2008
High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs
Sven Rottenberg, Janneke E Jaspers, Ariena Kersbergen, et al.
Cancer Research
|
August 24, 2016
The PARP Inhibitor AZD2461 Provides Insights into the Role of PARP3 Inhibition for Both Synthetic Lethality and Tolerability with Chemotherapy in Preclinical Models
Lenka Oplustil O'Connor, Stuart L Rulten, Aaron N Cranston, et al.
Journal of Medicinal Chemistry
|
September 20, 2008
4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1
Keith A Menear, Claire Adcock, Robert Boulter, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 24, 2021
Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in Combination with Carboplatin in Patients with Advanced Solid Tumors: A Phase I Study
Timothy A Yap, Matthew G Krebs, Sophie Postel-Vinay, et al.
British Journal of Cancer
|
November 3, 2018
pRAD50: a novel and clinically applicable pharmacodynamic biomarker of both ATM and ATR inhibition identified using mass spectrometry and immunohistochemistry
Gemma N Jones, Claire Rooney, Nicola Griffin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 27, 2013
ATM kinase inhibition preferentially sensitizes p53-mutant glioma to ionizing radiation
Laura Biddlestone-Thorpe, Muhammad Sajjad, Elizabeth Rosenberg, et al.
Genome Medicine
|
August 26, 2024
The PARP1 selective inhibitor saruparib (AZD5305) elicits potent and durable antitumor activity in patient-derived BRCA1/2-associated cancer models
Andrea Herencia-Ropero, Alba Llop-Guevara, Anna D Staniszewska, et al.
Analytical Chemistry
|
January 10, 2022
Method To Visualize the Intratumor Distribution and Impact of Gemcitabine in Pancreatic Ductal Adenocarcinoma by Multimodal Imaging
Nicole Strittmatter, Frances M Richards, Alan M Race, et al.
JCO Precision Oncology
|
January 15, 2026
Pathway for the Development of ATR Inhibitors in Pediatric Malignancies: An ACCELERATE Multistakeholder Analysis
Susanne A Gatz, Julia Glade-Bender, Andrew D J Pearson, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 54) with videos related to
Sort By:
Page
of 6
Journal of Medicinal Chemistry
|
February 17, 2016
Potent and Selective Inhibitors of MTH1 Probe Its Role in Cancer Cell Survival
Jason G Kettle, Husam Alwan, Michal Bista, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
October 31, 2008
High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs
Sven Rottenberg, Janneke E Jaspers, Ariena Kersbergen, et al.
Cancer Research
|
August 24, 2016
The PARP Inhibitor AZD2461 Provides Insights into the Role of PARP3 Inhibition for Both Synthetic Lethality and Tolerability with Chemotherapy in Preclinical Models
Lenka Oplustil O'Connor, Stuart L Rulten, Aaron N Cranston, et al.
Journal of Medicinal Chemistry
|
September 20, 2008
4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1
Keith A Menear, Claire Adcock, Robert Boulter, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 24, 2021
Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in Combination with Carboplatin in Patients with Advanced Solid Tumors: A Phase I Study
Timothy A Yap, Matthew G Krebs, Sophie Postel-Vinay, et al.
British Journal of Cancer
|
November 3, 2018
pRAD50: a novel and clinically applicable pharmacodynamic biomarker of both ATM and ATR inhibition identified using mass spectrometry and immunohistochemistry
Gemma N Jones, Claire Rooney, Nicola Griffin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 27, 2013
ATM kinase inhibition preferentially sensitizes p53-mutant glioma to ionizing radiation
Laura Biddlestone-Thorpe, Muhammad Sajjad, Elizabeth Rosenberg, et al.
Genome Medicine
|
August 26, 2024
The PARP1 selective inhibitor saruparib (AZD5305) elicits potent and durable antitumor activity in patient-derived BRCA1/2-associated cancer models
Andrea Herencia-Ropero, Alba Llop-Guevara, Anna D Staniszewska, et al.
Analytical Chemistry
|
January 10, 2022
Method To Visualize the Intratumor Distribution and Impact of Gemcitabine in Pancreatic Ductal Adenocarcinoma by Multimodal Imaging
Nicole Strittmatter, Frances M Richards, Alan M Race, et al.
JCO Precision Oncology
|
January 15, 2026
Pathway for the Development of ATR Inhibitors in Pediatric Malignancies: An ACCELERATE Multistakeholder Analysis
Susanne A Gatz, Julia Glade-Bender, Andrew D J Pearson, et al.
Page
of 6